GenFleet Therapeutics (Shanghai) Inc. made a strong Hong Kong Stock Exchange debut, with shares surging over 100% above the listing price amid renewed investor enthusiasm in biotech IPOs. The company raised approximately US$234 million, signaling robust capital market appetite for biotechnology firms on Asian exchanges. This performance reflects a broader comeback for regional biopharma investment amid favorable market conditions.